Strides Arcolab is currently trading at Rs. 1227.45, up by 5.65 points or 0.46% from its previous closing of Rs. 1221.80 on the BSE.
The scrip opened at Rs. 1195.00 and has touched a high and low of Rs. 1236.95 and Rs. 1190.00 respectively. So far 17888 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 1373.00 on 20-Aug-2015 and a 52 week low of Rs. 625.10 on 26-Sep-2014.
Last one week high and low of the scrip stood at Rs. 1236.95 and Rs. 1093.65 respectively. The current market cap of the company is Rs. 7316.06 crore.
The promoters holding in the company stood at 27.65% while Institutions and Non-Institutions held 45.94% and 26.41% respectively.
Pharmaceuticals firm Strides Arcolab has completed Rs 1,910 crore acquisition of Aspen Pharmacare’s generic pharmaceutical business and related assets in Australia. The transaction has now achieved closure on completion of closing conditions and statutory and regulatory approvals. The acquired business will be integrated and consolidated with Strides effective September 1, 2015.
Earlier in may 2015, Strides Arcolab’s subsidiary Strides Pharma Global Pte, Singapore and Strides (Australia) Pharma Pty, Australia signed definitive agreements with certain wholly owned subsidiaries of Aspen Pharmacare Holdings, a company listed on the Johannesburg Stock Exchange (Aspen), to acquire a generic pharmaceutical business in Australia together with certain branded pharmaceutical assets.
Strides Arcolab is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures wide range of IP-lead niche pharmaceutical products with an emphasis on sterile injectables.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1672.35 |
| Dr. Reddys Lab | 1236.30 |
| Cipla | 1238.15 |
| Zydus Lifesciences | 942.05 |
| Lupin | 2330.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: